



ASX / Media Release  
16 February 2021

## Invex Appoints Dr Megan Baldwin as Non-Executive Director

---

**Invex Therapeutics Ltd (Invex, ASX:IXC, or the Company)** a clinical-stage biopharmaceutical company focused on the development and commercialisation of Presendin™ (Exenatide) for neurological conditions relating to raised intracranial pressure, is pleased to announce that Dr Megan Baldwin has been appointed as an independent Non-Executive Director of the Company, effective 16 February 2021.

Dr Baldwin is CEO and Managing Director of Opthea Limited (ASX:OPT; NASDAQ:OPT), a late-stage biopharmaceutical company developing a novel therapy to address the unmet need in the treatment of retinal eye diseases, including wet age-related macular degeneration (wet AMD). Under Dr Baldwin's leadership, Opthea has rapidly advanced its ophthalmology program through Phase I and Phase II clinical development, was added to the S&P/ASX 300 in June 2020 and in October 2020 completed a \$180 million initial public offering (IPO) and listing on the US NASDAQ exchange to progress two pivotal Phase III studies in wet AMD.

Dr Baldwin is an experienced biotechnology executive, having over 20 years' experience working on therapeutic drug development programs for cancer and ophthalmic indications. Prior to Opthea, Dr Baldwin was employed at Genentech (now Roche) as a postdoctoral researcher before moving to Genentech's commercial division. Dr Baldwin also serves on the Board of Ausbiotech as Deputy Chair and is a welcome addition to the Board of Invex.

Dr Jason Loveridge, Chairman of Invex said "We are delighted that Megan has joined the Invex Board. Her substantial experience in drug development, regulatory engagement and clinical trial design and execution will be invaluable for Invex as the Company progresses Presendin™ into Phase III studies during 2021 to treat Idiopathic Intracranial Hypertension (IIH); a disease where up to one quarter of patients suffer permanent vision loss."

Dr Baldwin holds a PhD in Medicine from the University of Melbourne, having conducted her doctoral studies at the Ludwig Institute for Cancer Research, and is a member of the Australian Institute of Company Directors.

Pursuant to Dr Baldwin's appointment she will receive Non-Executive Director remuneration equating to \$50,000 per annum. Additionally, the Company will, subject to receipt of shareholder approval at the Company's next general meeting of shareholders, issue 400,000 options to acquire shares in the Company to Dr Baldwin, each with a strike price of \$1.10 calculated by applying a 31.8% premium to the five day Volume Weighted Average Price (VWAP) of Invex (ASX:IXC) shares up to and including 12 February 2021 of \$0.8345. The options will have a term of 3 years with vesting at 12 months and 24 months continued service with the Company.

- ENDS -

*This release dated 16 February 2021 has been authorised for lodgement to ASX by the Board of Directors of Invex Therapeutics and lodged by Narelle Warren, Company Secretary.*

---

**For more information, please contact:**

**Company/Investors**

Dr Thomas Duthy  
Executive Director  
[tduthy@invextherapeutics.com](mailto:tduthy@invextherapeutics.com)  
+61 402 493 727

**Media**

Margie Livingston  
Ignite Communications  
[margie@ignitecommunications.com.au](mailto:margie@ignitecommunications.com.au)  
+61 438 661 131

To subscribe to Invex email alerts, please visit [www.invextherapeutics.com](http://www.invextherapeutics.com) and follow us on Twitter **@InvexThera\_ASX**

## About Invex Therapeutics Ltd

---

Invex is a biopharmaceutical company focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised intracranial pressure, such as Idiopathic Intracranial Hypertension (IIH), acute stroke and traumatic brain injury. Invex has trademarked its repurposed Exenatide as Presendin™. [www.invextherapeutics.com](http://www.invextherapeutics.com).

## About Idiopathic Intracranial Hypertension (IIH)

---

IIH features severely raised intracranial pressure which causes disabling daily headaches and can compress the optic nerve, causing permanent vision loss in 25% of those affected. The usual age of onset is 20-30 years, and it is most common in women who are obese. IIH is a rapidly growing orphan indication: its incidence has increased by more than 350% in the last 10 years.